These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27737512)

  • 1. The Japanese Postmarketing Adverse Event Relief System: A Confluence of Regulatory Science, the Legal System, and Clinical Pharmacology.
    Tominaga T; Miyazaki S; Oniyama Y; Weber AD; Kondo T
    Clin Pharmacol Ther; 2017 Aug; 102(2):277-282. PubMed ID: 27737512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 3. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug makers are still giving gifts to doctors, F.D.A. officials tell senators.
    Harris G
    N Y Times Web; 2005 Mar; ():A15. PubMed ID: 15948332
    [No Abstract]   [Full Text] [Related]  

  • 5. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 10. [Analysis of Spontaneously Reported Adverse Events].
    Nakamura M
    Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmarketing surveillance: curriculum for the clinical pharmacologist. Part II: Clinical and regulatory considerations.
    Johnson JM; Tanner LA
    J Clin Pharmacol; 1993 Nov; 33(11):1015-22. PubMed ID: 8300884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xyrem (sodium oxybate) postmarketing adverse event reporting system.
    Wang YG
    Sleep Med; 2010 Jun; 11(6):595; author reply 595-6. PubMed ID: 20362501
    [No Abstract]   [Full Text] [Related]  

  • 13. [Research on foreign countries laws and regulations on surveillance and reporting of postmarketing drugs adverse reactions].
    Tian F; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(11):1464-7. PubMed ID: 19771884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety information in drug labeling: a comparison of the USA, the UK, and Japan.
    Shimazawa R; Ikeda M
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):306-18. PubMed ID: 23355452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 16. How should we react to adverse drug reactions?
    Ferner RE; Beard K
    Postgrad Med J; 2011 Feb; 87(1024):81-2. PubMed ID: 21303818
    [No Abstract]   [Full Text] [Related]  

  • 17. [Relief system for adverse drug reactions].
    Miyazaki S
    Nihon Rinsho; 2012 Aug; 70 Suppl 6():51-9. PubMed ID: 23156486
    [No Abstract]   [Full Text] [Related]  

  • 18. [Adverse events and adverse reactions associated with drugs--important actual spontaneous reporting of the drug event].
    Homma M
    Ryumachi; 1992 Oct; 32(5):429-31. PubMed ID: 1440077
    [No Abstract]   [Full Text] [Related]  

  • 19. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 20. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.